BACKGROUND: Adolescents and young adults (AYAs) with cancer are at risk for poor psychosocial outcomes. This study aimed to determine whether a novel intervention targeting resilience resources would improve patient-reported resilience, quality of life, and psychological distress. METHODS: In this parallel, phase 2 randomized controlled trial, English-speaking AYAs (12-25 years old) with cancer were randomized to the Promoting Resilience in Stress Management (PRISM) intervention or usual care (UC). PRISM is a brief, skills-based intervention targeting stress management, goal setting, cognitive reframing, and meaning making. Participants completed surveys at enrollment and 6 months. Mixed effects regression models evaluated associations between PRISM and the primary outcome (10-item Connor-Davidson Resilience Scale scores) and secondary outcomes (generic and cancer-related quality of life [Pediatric Quality of Life modules], psychological distress , and anxiety/depression [Hospital Anxiety and Depression]) at 6 months. RESULTS: Ninety-two AYAs were enrolled, were randomized, and completed baseline surveys (48 in the PRISM group and 44 in the UC group); 73% were 12 to 17 years old, and 62% had leukemia or lymphoma. Attrition was primarily due to medical complications and/or death; 36 PRISM participants and 38 UC participants completed 6-month surveys. PRISM was associated with improved resilience (+3.0 points; 95% confidence interval [CI], 0.5-5.4; P = .02) and cancer-specific quality of life (+9.6; 95% CI, 2.6-16.7; P = .01) and reduced psychological distress (-2.1; 95% CI, -4.1 to -0.2; P = .03) but not generic quality of life (+7.2; 95% CI, -0.8 to 15.2; P = .08). Although anxiety was similar between the groups, 2 PRISM participants (6%) and 8 UC participants (21%) met the criteria for depression at 6 months (odds ratio, 0.09; 95% CI, 0.01-1.09; P = .06). CONCLUSIONS: PRISM was associated with improved psychosocial outcomes in comparison with UC, suggesting that brief, skills-based interventions for AYAs may provide a benefit. Cancer 2018;124:3909-3917.
INTRODUCTION
Adolescents and young adults (AYAs; 12-25 years old) with cancer are at risk for poor psychosocial outcomes, in part because cancer disrupts normal developmental experiences such as the establishment of personal, social, and sexual identity and the pursuit of educational and vocational goals. [1] [2] [3] [4] [5] AYA cancer survivors report greater psychological distress and fewer positive health beliefs than younger pediatric or older adult counterparts. 6 Impaired physical, social, and emotional health during and after cancer therapy are common. 7, 8 These challenges may translate into underemployment, excessive medical expenditures, and significant corresponding productivity losses. 9 Inadequate psychosocial support and underdeveloped skills for navigating adversity may exacerbate these challenges. 7, [10] [11] [12] Although few studies have described positive outcomes among AYA patients with chronic disease, 13 resilience (defined as the process of harnessing resources to sustain physical and emotional well-being in the face of significant stress) represents a promising approach.
14 Promoting resilience resources (eg, skills in stress management, goal setting, cognitive reframing, and meaning making) may be valuable. 15 For example, among older adults with cancer, stress management reduces depression, 16 goal seeking and problem solving improve psychosocial health, 16 and mindfulness improves quality of life. 17 Reductions in stress and distress improve immune function and reduce morbidity and mortality.
Cancer October 1, 2018 Unfortunately, delivering traditional psychosocial interventions is challenging among AYAs with serious illness. More than one-third decline traditional cognitive behavioral therapy (CBT), and an additional one-third discontinue participation because of CBT's typical time commitment. 21 AYAs learn and communicate differently than younger and older patients, and this necessitates age-targeted language and educational methods. 22 Finally, CBT is designed for patients with maladaptive coping; AYAs may avoid the development of maladaptive behaviors through preventive learning.
Although the need for targeted psychosocial care for AYAs with cancer is well established, few interventions have been evaluated in randomized controlled trials. 23 Hence, we developed and demonstrated the feasibility and acceptability of a novel, developmentally appropriate, brief, skills-based psychosocial intervention targeting resilience resources: Promoting Resilience in Stress Management (PRISM). 24, 25 In this randomized controlled trial, we aimed to determine whether PRISM improved psychosocial outcomes in comparison with psychosocial usual care (UC). We hypothesized that PRISM would be associated with improved patient-reported resilience, quality of life, and psychological distress.
MATERIALS AND METHODS

Design, Setting, and Participants
We conducted this phase 2, parallel, 1:1 randomized controlled trial at Seattle Children's Hospital between January 2015 and October 2016. Eligible participants were 1) 12 to 25 years old, 2) fluent in English, and 3) either diagnosed with new cancer 1 to 10 weeks before enrollment and receiving systemic chemotherapy or diagnosed with progressive, recurrent, or refractory cancer at any time before enrollment. Because of the nature of the intervention, patients determined by clinical staff to have preexisting or cancer-associated cognitive disabilities were excluded. The Seattle Children's Hospital institutional review board approved the study.
Recruitment and Randomization
Study staff identified potential participants through clinic rosters and approached them in outpatient clinics or inpatient wards. After discussion about the study, adolescents (12-17 years old) provided written assent, and their parents provided written consent. Young adults (18-25 years old) provided written consent.
Consecutive eligible, consented patients were enrolled until we reached our target enrollment of 100 (Fig. 1) .
The sample size was determined from preliminary data suggesting that AYA scores on the 10-item ConnorDavidson Resilience Scale (CDRISC-10; the primary outcome) were normally distributed with a mean of 31 (standard deviation, 5.3). Defining the minimal clinically important difference (MCID) as half the standard deviation 26 and anticipating 10% attrition, we found that a final sample of 90 (45 per arm) provided 80% power with a 2-sided α value of .05 to detect the MCID in patient-reported resilience.
Participants were assigned 1:1 to UC alone or UC plus PRISM. The randomization algorithm was constructed with permuted blocks of various sizes; schedules were stratified by age (12-17 vs 18-25 years) because intervention materials were written at the developmental levels of these 2 age groups. Staff were blinded to the randomization scheme until after enrollment.
Psychosocial UC
All participants received psychosocial UC. At our center, this includes an assigned social worker who conducts comprehensive psychosocial assessments at the time of diagnosis and then provides services ad hoc throughout the illness. Services range from behavioral health to financial, housing, and other concrete support. In addition, our AYA oncology program includes subspecialty multidisciplinary psychosocial services upon family request or staff referral.
PRISM Intervention
PRISM was built on the basis of theories of resilience and stress and coping plus successful interventions described in other populations. 25 It is based on traditional CBT methods but deliberately deviates in that it is delivered preventatively with brief, skills-based training. It is manualized (eg, it has been standardized through comprehensive protocols outlining training, delivery, and maintenance of fidelity). The initial design was refined through iterative testing with detailed feedback from AYA patients and families. We have previously described PRISM's feasibility, acceptability, and preliminary evidence of efficacy.
25
Content
PRISM consists of 4 one-on-one sessions, each 30 to 50 minutes long, delivered approximately every other week (Table 1) . 25 "Stress management" focuses on mindfulness skills, including deep breathing, relaxation, and awareness of stressors. "Goal setting" teaches skills such as identifying realistic, concrete, and actionable goals,
planning steps toward their achievement, and preparing for roadblocks. "Cognitive restructuring" trains participants to recognize negative emotions and demoralizing self-talk and helps them to reframe perceptions realistically and/or more positively. "Benefit finding" focuses on finding meaning from difficult situations, including cancer, and identifying gratitude.
An optional fifth session called "coming together" involves a facilitated family meeting in which participants share learned skills with loved ones (Table 1) . Between sessions, participants receive worksheets to further develop skills. After the completion of all 4 main sessions, interventionists visit once monthly for boosters where participants can practice select skills.
Delivery
PRISM was administered by trained, bachelor's degreelevel nonclinical staff. 25 All interventionists received ≥8 hours of standardized training, including mock sessions with role playing. For the current study, we trained 7 baccalaureate-educated women research associates without advanced degrees otherwise. Four functioned as core interventionists, and 3 functioned as backup. One interventionist delivered all sessions to a given family. Each session was administered in a private patient room during inpatient hospital stays or before/after outpatient clinic visits.
Fidelity
All PRISM sessions were audio-recorded. For each interventionist, the first 5 sessions and 1 of any 5 randomly selected sessions were scored for fidelity with a standardized tool. 25, 27 Although our protocol included processes to retrain interventionists if needed, no remediation was necessary.
Study Instruments
Demographic variables were requested in surveys and collected from the medical record if missing. Additional medical record extraction included the cancer type and history of advanced cancer (defined as recurrent, refractory, or progressive disease). All participants were invited to complete a survey consisting of AYA age-validated instruments upon enrollment (before any PRISM sessions, where relevant) and 6 months later. The survey included patient-reported:
1. Resilience. The CDRISC-10 assesses self-perceived resilience by querying how an individual typically handles adversity. 28 Items are scored on a 5-point Likert scale; total scores range from 0 to 40, with higher scores reflecting greater resilience. 2. Quality of life. The Pediatric Quality of Life (PedsQL) Generic Short-Form and Cancer Modules assess general physical, emotional, social, and school well-being and cancer-related symptoms, worries, cognition, and communication, respectively. 29, 30 Total scores range from 0 to 100; higher scores represent better quality of life. 3. Psychological distress. The Kessler-6 Psychological Distress Scale measures the level of global psychological distress. 31, 32 Scores range from 0 to 24 points; higher scores reflect greater distress, and scores > 12 suggest high distress. 4. Anxiety and depression. The Hospital Anxiety and Depression Scale (HADS) assesses anxiety and depression in patients with serious illness. 33 Caseness is defined as a score >7 points in the relevant subdomain.
Procedures
After randomization, staff reconvened with each family to share their assignment and deliver the baseline survey. PRISM sessions were scheduled approximately every other week. Participants or parent delegates received in-person, phone, and/or e-mail reminders 7 days before each session or survey due date. When surveys were not returned, staff contacted participants once weekly for 3 weeks. Surveys were considered missing if not received within 12 weeks. Although our feasibility studies suggested that PRISM was not associated with high psychological distress, we reviewed surveys within 72 hours for this potential adverse event. 31 Participants received a $25 or $50 gift card upon completion of the baseline or 6-month survey, respectively.
Outcomes
The primary outcome was patient-reported resilience at 6 months. Secondary outcomes included other instrument scores and anxiety/depression at 6 months. Exploratory analyses assessed mean score trajectories from the baseline to 6 months.
Statistical Analyses
In this primary intention-to-treat analysis, data were analyzed and reported as planned. We included data from all patients who completed baseline surveys. Unadjusted linear mixed effects regression modeling with patient-level 
RESULTS
During the 22-month enrollment period, we assessed 483 patients for eligibility (Fig. 1) . Of 130 eligible AYAs, 100 (77%) were enrolled, and they were randomized (50 to UC and 50 to PRISM). There were no demographic differences between eligible patients who did and did not enroll. One PRISM participant was identified as ineligible immediately after his randomization. He was unenrolled and did not receive a baseline survey.
Six UC participants (12%) did not complete the baseline surveys (5 electively and 1 on account of medical complications severely impairing her cognition). One PRISM participant (2%) elected not to complete the baseline survey.
Among the remaining 92 participants (44 UC participants and 48 PRISM participants), there were no differences between the groups with respect to clinical or demographic characteristics except for sex and first language ( Table 2 ). All 48 PRISM participants received at least 1 session, 43 (90%) received all 4 main sessions, and 40 (83%) opted in for coming together (Fig. 1) . Reasons for attrition between the baseline and 6-month follow-up surveys were predominantly medical complications or death (4 UC participants [9%] and 10 PRISM participants [21%]; Fisher's exact P = .25). Thirty-eight UC participants and 36 PRISM participants completed 6-month surveys (median completion time, 8 days after the 6-month due date; interquartile range, 8-17 days).
At 6 months, PRISM was associated with higher patient-reported resilience (+3.0 points; 95% confidence interval [CI], 0.5-5.4) and cancer-specific quality of life (+9.6; 95% CI, 2.6-16.7) and lower psychological distress (-2.1; 95% CI, -4.1 to -0.2) but not higher generic quality of life (+7.2; 95% CI, -0.8 to 15.2; P = .08; Table 3 ). Effect sizes were small to moderate. Changes in resilience and cancer-specific quality of life met or exceeded the MCID. No PRISM participants reported high distress. Cancer October 1, 2018 Among the 74 with 6-month survey data, 6 PRISM participants (17%) and 10 UC participants (26%) met criteria for anxiety (odds ratio, 0.36; 95% CI, 0.07-1.96), whereas 2 PRISM participants (6%) and 8 UC participants (21%) met criteria for depression (odds ratio, 0.09; 95% CI, 0.01-1.09). Exploratory analyses suggested divergent trajectories of instrument scores (Fig. 2) . For example, resilience and quality-of-life scores among UC participants went down or remained unchanged, whereas PRISM participants' scores went up.
DISCUSSION
AYAs with cancer may be vulnerable to poor psychosocial outcomes because their disease disrupts normal, pivotal developmental processes. Although there has been a call for age-appropriate interventions to improve these outcomes, few have been tested in randomized trials. In this randomized controlled trial, a novel, patient-centered, brief, skills-based intervention targeting resilience resources (PRISM) was associated with improved patient-reported resilience, cancer-related quality of life, and psychological distress. Patients who received PRISM showed a trend toward lower rates of depression. Furthermore, there were no adverse events related to study participation.
Additional successes were enrollment and retention rates among PRISM participants. Fewer than 50% of American AYAs with cancer enroll in clinical trials. 35 Qualitative analyses suggest that the stress associated with a new cancer diagnosis limits enrollment, whereas directed patient engagement in consent discussions facilitates it. 36 Our enrollment rate of 77% among eligible patients was higher than rates in published studies, perhaps because we waited to approach patients until at least 2 weeks after their diagnosis and directly engaged them in consent discussions.
After randomization, only 1 PRISM participant (2%) failed to complete the baseline survey. Forty-three of the remaining 48 participants (90%) completed all 4 main intervention sessions. These observations may be due to the fact that PRISM's design incorporates stakeholder-identified preferences for content and format. 37, 38 It is also deliberately brief and allows participants to share personal narratives; this is another variable associated with AYA engagement in clinical research. 39 Even with these successes, there are important limitations. Our enrollment may be attributable to our large, academic, pediatric-based AYA oncology center, where participation in clinical research is common. 40 Results may not be generalizable to smaller, community-based, or adult oncology centers. Similarly, our UC involves a multidisciplinary psychosocial team, which may not be available elsewhere. Although we did not educate staff about PRISM's details, they may have been aware of its content. We cannot determine if or how they used that awareness in ongoing psychosocial supportive care, nor if it influenced the frequency of their visits. PRISM's benefit may, therefore, be different elsewhere.
Despite our high enrollment rate, more UC participants than PRISM participants declined continued participation after randomization and before baseline survey completion. This may be because they perceived a lack of benefit from the control arm. We cannot determine whether this group had different baseline psychological characteristics, nor can we assess how attrition affected study findings.
We included only English-speaking patients because PRISM has been validated only in English. To increase diversity, we enrolled AYAs who spoke English as a second language, yet this group is not necessarily representative of non-English speakers. By chance, more UC participants than PRISM participants spoke English as a second language and/or were female. Although sensitivity Linear models were based on 92 participants with baseline data; logistic models were based on 74 participants with 6-month data. a Half the standard deviation of mean pooled baseline scores. 26 Cancer October 1, 2018 analyses suggested that these differences did not influence findings, our sample size may have been too small to detect subtle biases. PRISM's apparent efficacy may be because primary English speakers or young men are more responsive. Likewise, cultural differences in perceptions of resilience warrant further investigation regarding if and how PRISM could be adapted effectively. There are several conceptualizations of resilience. 41, 42 We define resilience as a process of harnessing resources to sustain well-being, and we postulate that AYAs, especially those with serious illness, may have underdeveloped resources. PRISM's proposed mechanism of action is to bolster these resources and, in turn, enable AYA well-being. We used the CDRISC-10 to assess resilience because it is an age-appropriate, validated instrument for measuring our primary outcome of interest: AYAs' perceptions of their own resilience. However, the construct of resilience, as assessed by the Connor Davidson Resilience Scale, has been associated with variable traits, states, processes, and outcomes such as hardiness, affect, coping, and life satisfaction. 43 It may not exclusively reflect an AYA's ability to harness resilience resources, nor do CDRISC-10 scores clearly translate into meaningful clinical implications. Hence, we also assessed PRISM's impact on key surrogate outcomes indicative of resilience, namely quality of life and decreased psychological distress.
Because 90% of PRISM recipients received all 4 main sessions, we cannot delineate PRISM's active ingredients or a dose effect. We did not track the real-life application of PRISM skills, so we cannot measure its uptake. We chose to measure patient-reported outcomes at 6 months to capture PRISM's effects shortly after its completion. We cannot assess the durability of outcome improvements or the persistence of PRISM-developed skills.
Finally, to compare PRISM with established UC, we avoided an active control (eg, a control arm with similar personal contact and different information delivery). 44 It is possible that PRISM's impact is due to the social aspect of its delivery, rather than its content, because social support is a key factor of AYA patient-reported well-being. 45 Taken together, these findings have implications for clinical practice and future research. Compared with UC, PRISM was associated with clinically significant improvements in psychosocial health with moderate effect sizes. These findings are promising because meta-analyses suggest that even small effect sizes of positive psychology interventions are associated with meaningful patient-centered outcomes. 46 Although future research is needed to examine the duration of PRISM's efficacy, its active ingredients, and strategies for its dissemination and implementation, PRISM represents a promising approach to improving outcomes in an otherwise vulnerable and high-risk population.
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